FBLG
FibroBiologics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.40
−5.72%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.45
From 52W high−88.56%
Volume95605.00
Market cap$9.74M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$1.45
From 52W high
−88.56%
Volume
95605.00
Market cap
$9.74M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
P/E (TTM)
—
RSI (14)
48.5
MomentumView details →
1D Return
−5.72%
YTD Return
−68.44%
SummaryUpdated Jun 1, 2026
FibroBiologics, Inc. (NASDAQ:FBLG) is a clinical-stage biotechnology company founded in 2021 and headquartered in Houston, Texas. The company went public in February 2024 and focuses on developing innovative cell therapy treatments using fibroblasts, a type of connective tissue cell. As a pre-revenue biotech firm, FibroBiologics is currently advancing multiple therapeutic candidates through clinical trials, targeting conditions ranging from spinal disc degeneration to multiple sclerosis and cancer treatment.
Similar companies
Latest newsMore news →
FibroBiologics, Inc. issued 298,508 shares of common stock and warrants to purchase up to 298,508 shares to Chief Scientific Officer Hamid Khoja at $1.675 per unit, raising approximately $0.5 million in a private placement.5d agoFibroBiologics released the third batch of its CYWC628 drug product and shipped it to Australia to support its ongoing Phase 1/2 clinical trial for diabetic foot ulcers.24d agoFibroBiologics completed manufacturing of the third batch of its CYWC628 drug product for a Phase 1/2 clinical trial in patients with diabetic foot ulcers.75d ago